Cardiol FDA >>> Led by David Elsley, Cardiol is already approved by the FDA in trials. Heart Disease is their target.
TSX: CRDL
OTCQX: CRTPF
FSE: CT9
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease.
This is a company that has made pretty strong progress in the fight for health. Particularly in this new fight against covid-19. Cardiol has received approval from the FDA for both Phase 2 and 3 clinical trials in order to test the efficacy of their CardiolRx in improving outcomes for covid-19 patients who have cardiovascular diseases. This is pretty good progress in a short time frame that this virus has been present.
Cardiol specializes in health healthcare, so this is straight up their alley.
The company's leadership of David Elsley as President and CEO is bringing tons of experience to to table. He helmed another heart health company starting back in 1990. Eventually it went public on the TSX and Nasdaq by raising over $200 million dollars and a market cap of over a billion. This is someone who is not afraid of heights and can hold their own in the big leagues.
Cardiol holds great collaborations with three research facilities at the moment. Including:
* University of Alberta
* TecSalud del Tecnologico de Monterrey, and
* Debaket Heart & Vascular Center
Their finances are pre-revenues as they are still in trials, as expected. Their Assets are strong at just under $16M with essentially no debt on the books. They hold less than $200K in total debt. A great place to be at the start of any company, the longer they can hold this the better.
This is not financial advice!!